



**Contact:** Neal G. Simon  
**Location:** Bethlehem, PA  
**Email:** ngsimon@azevan.com  
**Tel:** 610-419-1057  
**Website:** www.azevan.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

## Company Profile

**Industry Sector:** Pharmaceuticals

**Company Overview:** Azevan Pharmaceuticals, Inc. is developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company brought its first candidate, SRX251, through a successful Phase I trial in 2008. Its second candidate, SRX246, entered first-in-human trials in Q2 2009.

**Target Market(s):** Anxiety, Depression, Women's Health & Pain, Raynaud's Disease

## Key Value Drivers

**Technology\*:** The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates.

**Competitive Advantage:** The Company's lead clinical candidates, SRX251 and SRX246, are first-in-class, CNS-penetrating, high affinity, high selectivity V1a receptor antagonists that are orally bioavailable.

**Plan & Strategy:** The Company is developing additional candidates to strengthen its pipeline while positioning for partnering and additional financing opportunities. Azevan has a flexible approach to partnerships for CNS and Women's Health indications (by geography, co-promotion, and/or co-development).

\*Technology funded by the NIMH and being commercialized under the NIH-CAP

## Management

### Leadership:

Neal G. Simon, CEO  
 Eve Damiano, Sr. VP Operations  
 Craig F. Ferris, Chief Biological Sciences

### Scientific Advisory Board:

Stephen Benkovic, Ph.D.  
 Michael Brownstein, M.D., Ph.D.  
 David Rubinow, M.D.  
 Meir Steiner, M.D., Ph.D., FRCP

## Product Pipeline

Product	Lead Optimization	Pre-clinical	IND Filing	Phase I	Phase II
SRX246 (V1a) Anxiety/PTSD				Q2 09	
SRX246 (V1a) Depression					
AVN628 (V1a/V1b) Anxiety/Depression					
SRX251 (V1a) Primary Dysmenorrhea					
SRX251(V1a) PMS/ PMDD					
SRX251(V1a) Raynaud's					